Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind North American Phase III trial in 569 patients, palonosetron met the primary endpoint of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury